Guanidine Hydrochloride

(Aminoguanidine)

PreclinicalSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Guanidine Hydrochloride is one of 32 small molecule programs targeting Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

StressCompleted

AsthmaPreclinical

Active, not recruiting

StressPreclinical

Completed

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Aclidinium Bromide

Atrovent

2 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetic1 trial

Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients

Completed·UUniversity of Minnesota·Phase 1·NCT02099981·34 enrolled

Endotoxemia1 trial

Effect of Selective iNOS Inhibition During Human Endotoxemia

Completed·RRadboud University Medical Center·Phase 1·NCT00184990·7 enrolled

Asthma1 trial

Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects

Completed·IImperial College London·N/A·NCT00159380·16 enrolled

Stress1 trial

NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD

Completed·IImperial College London·N/A·NCT00180635·30 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

GUANIDINE HYDROCHLORIDE

NDA NDA001546

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Aminoguanidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aminoguanidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aminoguanidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA001546). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Guanidine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetic1 trial

Endotoxemia1 trial

Asthma1 trial

Stress1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News